论文部分内容阅读
[目的]观察体部伽玛刀联合培美曲塞/卡铂与联合紫杉醇/卡铂同步治疗局部晚期非小细胞肺癌的临床疗效及毒副反应。[方法]62例局部晚期非小细胞肺癌患者,随机分为A、B两组。A组30例,给予体部伽玛刀放疗,同步联合培美曲塞/卡铂方案化疗;B组32例,给予伽玛刀同步联合紫杉醇/卡铂方案化疗。评价两组的临床疗效和毒副反应。[结果]A组和B组近期有效率(CR+PR)分别为83.33%和81.25%,两组间差异无统计学意义(P>0.05);A组1、2年生存率及中位生存期分别为73.33%、43.33%和17.5个月,B组则分别为68.75%、37.50%和16.9个月;A组与B组比较,无统计学差异(P>0.05)。A组毒副反应低于B组(P<0.05)。[结论]体部伽玛刀联合培美曲塞/卡铂与联合紫杉醇/卡铂同步治疗局部晚期非小细胞肺癌具有良好并相似的临床疗效,但前者具有更好的安全性和可耐受性。
[Objective] To observe the clinical efficacy and side effects of body gamma knife combined with pemetrexed / carboplatin and paclitaxel / carboplatin in the treatment of locally advanced non-small cell lung cancer. [Method] Sixty-two patients with locally advanced non-small cell lung cancer were randomly divided into A and B groups. Group A (n = 30) received radiotherapy with gamma knife radiotherapy, combined with pemetrexed / carboplatin chemotherapy. Group B (n = 32) received gamma knife combined with paclitaxel / carboplatin chemotherapy. The clinical efficacy and side effects of the two groups were evaluated. [Results] The effective rates (CR + PR) in group A and group B were 83.33% and 81.25% respectively, with no significant difference between the two groups (P> 0.05). The 1-year and 2-year survival rates and median survival (73.33%, 43.33% and 17.5 months respectively) in group B and 68.75%, 37.50% and 16.9 months in group B, respectively. There was no significant difference between group A and group B (P> 0.05). The side effects in group A were lower than those in group B (P <0.05). [Conclusion] Gamma knife combined with pemetrexed / carboplatin and paclitaxel / carboplatin in the treatment of locally advanced non-small cell lung cancer have good and similar clinical efficacy, but the former has better safety and tolerability Sex.